Evidence map›Paper›PMID 30760125›Full record

Trial reportCurrent medical research and opinion2019

Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.

Priscilla Hollander, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory Golm, Susan Huyck, Steven G Terra, James P Mancuso, Samuel S Engel, Brett Lauring and 1 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Current medical research and opinion, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01999218. Cited by 20 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 10 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01999218 phase3completed

A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

Ran2013Enrolled1,326Registered outcomes6Posted comparisons12ConditionsType 2 Diabetes MellitusArmsErtugliflozin 10 mg, Ertugliflozin 5 mg, Glimerpiride, Metformin, Placebo to Ertugliflozin
Open the trial in the graph
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 10 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Article
  15. Review
  16. Review
  17. Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
    Article
  18. Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020
    Article
  19. Article
  20. SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects.International journal of environmental research and public health · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Priscilla Hollandera Baylor Endocrine Center , Dallas , TX , USA.
Julie Hillb Merck & Co. Inc. , Kenilworth , NJ , USA.
Jeremy Johnsonb Merck & Co. Inc. , Kenilworth , NJ , USA.
Zhi Wei Jiangc MSD R&D (China) Co. Ltd , Beijing , China.
Gregory Golmb Merck & Co. Inc. , Kenilworth , NJ , USA.
Susan Huyckb Merck & Co. Inc. , Kenilworth , NJ , USA.
Steven G Terrad Pfizer Inc. , Andover , MA , USA.
James P Mancusoe Pfizer Inc. , Groton , CT , USA.
Samuel S Engelb Merck & Co. Inc. , Kenilworth , NJ , USA.
Brett Lauringf formerly of Merck & Co. Inc. , Kenilworth , NJ , USA.
Jie Liub Merck & Co. Inc. , Kenilworth , NJ , USA.
Merck & Co., Inc., Rahway, NJ, USA (United States) · USPfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bridged Bicyclo Compounds, HeterocyclicHypoglycemic AgentsSulfonylurea CompoundsBlood PressureBody WeightDiabetes Mellitus, Type 2FemaleHumansMaleMetforminMiddle AgedBridged Bicyclo Compounds, HeterocyclicertugliflozinglimepirideHypoglycemic AgentsMetforminSulfonylurea Compoundsertugliflozinglimepirideglycemic controlsodium–glucose cotransporter 2 inhibitorsulfonylureaType 2 diabetes mellitus

Identifiers

PMID30760125
OpenAlexW2912945316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.